DUSP4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14133570	0.59	1/20
SCHEMBL14132635	0.59	1/20
SCHEMBL13856710	0.59	1/20
SCHEMBL22259725	0.57	1/20
SCHEMBL14133357	0.57	1/20
SCHEMBL4412367	0.56	1/20
SCHEMBL4412376	0.56	1/20
SCHEMBL3389978	0.54	1/20
SCHEMBL3389983	0.54	1/20
SCHEMBL31418349	0.54	1/20
SCHEMBL2065640	0.54	1/20
SCHEMBL2065642	0.54	1/20
SCHEMBL2181282	0.54	1/20
SCHEMBL13345210	0.54	1/20
SCHEMBL12892076	0.53	1/20
SCHEMBL14133409	0.53	1/20
SCHEMBL14132901	0.52	1/20
SCHEMBL3391203	0.52	1/20
SCHEMBL3391207	0.52	1/20
SCHEMBL14132664	0.52	1/20

Clinical trials — most relevant to DUSP4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans	PHASE4	COMPLETED
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies	PHASE1	COMPLETED
Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)	EARLY_PHASE1	COMPLETED
Steroid Resistance During COPD Exacerbations With Respiratory Failure	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane	nan	UNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a DUSP4 binder may also engage these)

Protein	Name	Similarity
Q62767	—	1.000	Q62767 →
Q8BFV3	—	1.000	Q8BFV3 →
P28563	—	1.000	P28563 →
Q64623	—	0.998	Q64623 →
Q9PW71	—	0.996	Q9PW71 →
Q63340	—	0.994	Q63340 →
O54838	—	0.994	O54838 →
Q91Z46	—	0.994	Q91Z46 →
Q16829	—	0.992	Q16829 →
DUSP6	Dual specificity protein phosphatase 6	0.992	landscape →
Q2KJ36	—	0.991	Q2KJ36 →
Q9DBB1	—	0.991	Q9DBB1 →
Q90W58	—	0.990	Q90W58 →
DUSP1	Dual specificity protein phosphatase 1	0.989	landscape →
DUSP5	Dual specificity protein phosphatase 5	0.989	landscape →
Q64346	—	0.989	Q64346 →
Q91790	—	0.988	Q91790 →
Q9VVW5	—	0.982	Q9VVW5 →
Q0IID7	—	0.981	Q0IID7 →
Q9ESS0	—	0.980	Q9ESS0 →
Q99956	—	0.979	Q99956 →
Q9JIM4	—	0.979	Q9JIM4 →
DUSP10	Dual specificity protein phosphatase 10	0.978	landscape →
Q9D0T2	—	0.977	Q9D0T2 →
Q8BK84	—	0.976	Q8BK84 →
O43304	—	0.975	O43304 →
Q05922	—	0.974	Q05922 →
Q9UNI6	—	0.974	Q9UNI6 →
P0C595	—	0.973	P0C595 →
A2AP18	—	0.973	A2AP18 →